Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q1 2017 · 10-Q
Revenue$10.51M$10.51M−66.4% vs Q1 2016 Net Income-$66.17M-$66.17MN/M vs Q1 2016 EPS Diluted-$1.56-$1.56N/M vs Q1 2016 Operating Income-$67,047,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
Free Cash Flowderived-$74,367,000N/M Margins · derivedOperating margin-638.1%−562.6 pt vs Q1 2016
Net margin-629.7%−555.5 pt vs Q1 2016
ended Mar 31, 2017 · filed May 4, 2017 · 34 d after period end